Corona Remedies’ Rs 655-crore IPO entered Day 2 after achieving 62% subscription on Day 1, driven largely by retail demand. The IPO’s grey market premium of Rs 262 signals strong interest despite slight softening. Listing is expected around December 15, supported by solid financial performance and strong brand-led growth.